IL147017A0 - TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES - Google Patents
TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIESInfo
- Publication number
- IL147017A0 IL147017A0 IL14701700A IL14701700A IL147017A0 IL 147017 A0 IL147017 A0 IL 147017A0 IL 14701700 A IL14701700 A IL 14701700A IL 14701700 A IL14701700 A IL 14701700A IL 147017 A0 IL147017 A0 IL 147017A0
- Authority
- IL
- Israel
- Prior art keywords
- prostate cancer
- erbb2 antibodies
- treating prostate
- erbb2
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14131599P | 1999-06-25 | 1999-06-25 | |
PCT/US2000/017423 WO2001000238A1 (en) | 1999-06-25 | 2000-06-23 | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
IL147017A0 true IL147017A0 (en) | 2002-08-14 |
Family
ID=22495163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14701700A IL147017A0 (en) | 1999-06-25 | 2000-06-23 | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
Country Status (18)
Country | Link |
---|---|
US (2) | US20060083739A1 (de) |
EP (1) | EP1189634B1 (de) |
JP (2) | JP4579471B2 (de) |
KR (1) | KR100754049B1 (de) |
CN (1) | CN100381172C (de) |
AT (1) | ATE355079T1 (de) |
AU (1) | AU779209B2 (de) |
BR (1) | BR0012195A (de) |
CA (1) | CA2383493C (de) |
CY (1) | CY1107637T1 (de) |
DE (1) | DE60033658T2 (de) |
DK (1) | DK1189634T3 (de) |
ES (1) | ES2282120T3 (de) |
IL (1) | IL147017A0 (de) |
MX (1) | MXPA01013395A (de) |
PT (1) | PT1189634E (de) |
WO (1) | WO2001000238A1 (de) |
ZA (1) | ZA200110088B (de) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
EP2283867B1 (de) * | 1999-06-25 | 2014-05-21 | ImmunoGen, Inc. | Methoden zur behandlung unter verwendung von erb antibody-mayntasinoid konjugate |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
CN100340575C (zh) * | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6825333B1 (en) | 1999-08-20 | 2004-11-30 | Chiron Corporation | EGFH2 genes and gene products |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
CN102698265A (zh) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
AU2003226065B2 (en) * | 2002-04-12 | 2009-02-26 | Ludwig Institute For Cancer Research, Ltd | Recombinant anti-interleukin-9 antibodies |
AU2003237367A1 (en) | 2002-06-03 | 2003-12-19 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
AU2003238871B2 (en) * | 2002-06-05 | 2009-04-23 | Cedars-Sinai Medical Center | Method of treating cancer using kinase inhibitors |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
EP1698640B2 (de) | 2003-10-01 | 2019-06-19 | Kyowa Hakko Kirin Co., Ltd. | Verfahren zur stabilisierung von antikörpern und stabilisierte antikörperzubereitung vom lösungstyp |
JP4905624B2 (ja) * | 2003-10-31 | 2012-03-28 | 学校法人 久留米大学 | ペプチドワクチン投与およびエストラムスチン処置の併用療法 |
AU2003280688A1 (en) * | 2003-10-31 | 2005-05-19 | Kurume University | Combination therapy of peptide vaccination and estramustine treatment |
EP1737489B1 (de) | 2004-04-08 | 2012-01-11 | David B Agus | ErbB2-Antagonisten für die Tumorschmerztherapie |
GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
KR20180091967A (ko) * | 2004-07-22 | 2018-08-16 | 제넨테크, 인크. | Her2 항체 조성물 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006063042A2 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
KR20170134771A (ko) | 2005-01-21 | 2017-12-06 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
KR101253576B1 (ko) | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Her 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
EP1913958B1 (de) * | 2006-08-03 | 2009-12-23 | Sanofi-Aventis | Antitumorale Zusammensetzungen enthaltend Acetylcyclopropyl Docetaxel und Trastuzumab |
SG174090A1 (en) | 2006-08-21 | 2011-09-29 | Hoffmann La Roche | Tumor therapy with an anti-vegf antibody |
EP2899541A1 (de) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression |
PL2171090T3 (pl) | 2007-06-08 | 2013-09-30 | Genentech Inc | Markery ekspresji genów odporności guza na leczenie hamujące HER2 |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
WO2008157490A1 (en) * | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Synergistic treatment of cells that express epha2 and erbb2 |
BRPI0821906B1 (pt) | 2008-01-03 | 2022-06-07 | The Scripps Research Institute | Anticorpo isolado de comprimento total, seu uso, polinucleotideo, vetor, e célula hospedeira |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
HUE025507T2 (en) | 2008-03-18 | 2016-02-29 | Genentech Inc | Combinations of anti-HER2 antibody-drug conjugate and chemotherapeutic agents and methods for their use |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
EP2362783A2 (de) | 2008-10-31 | 2011-09-07 | Biogen Idec MA Inc. | Licht-targeting-moleküle und ihre anwendungen |
AR075896A1 (es) | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
JP5981853B2 (ja) | 2010-02-18 | 2016-08-31 | ジェネンテック, インコーポレイテッド | ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用 |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2576621B1 (de) | 2010-05-27 | 2019-04-10 | Genmab A/S | Monoklonale antikörper gegen her2 |
EP2575880B1 (de) | 2010-05-27 | 2019-01-16 | Genmab A/S | Monoklonale antikörper gegen her2-epitop |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
EP2643353A1 (de) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispezifische moleküle |
EP2655413B1 (de) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung |
WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
CN106432506A (zh) | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
KR20140057326A (ko) | 2011-08-17 | 2014-05-12 | 제넨테크, 인크. | 뉴레귤린 항체 및 그의 용도 |
US20130095172A1 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
CN106987620A (zh) | 2011-11-30 | 2017-07-28 | 霍夫曼-拉罗奇有限公司 | 癌症中的erbb3突变 |
EP2788500A1 (de) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identifizierung von non-respondern auf her2-inhibitoren |
US20130195851A1 (en) | 2011-12-23 | 2013-08-01 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
WO2013148315A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
KR102291355B1 (ko) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
KR20140103554A (ko) * | 2013-02-18 | 2014-08-27 | 고려대학교 산학협력단 | sLZIP 단백질을 포함하는 안드로겐 의존성 전립선암 치료용 의약 조성물 |
CN105451767B (zh) | 2013-03-15 | 2019-10-18 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
CA3071678A1 (en) | 2013-04-16 | 2014-10-23 | Genentech,Inc. | Pertuzumab variants and evaluation thereof |
SG10201809411PA (en) | 2014-04-25 | 2018-11-29 | Genentech Inc | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
CN107614015A (zh) | 2015-05-30 | 2018-01-19 | 豪夫迈·罗氏有限公司 | 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法 |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
EP3534948A1 (de) | 2016-11-04 | 2019-09-11 | Genentech, Inc. | Behandlung von her2-positivem brustkrebs |
CN110099926A (zh) | 2016-12-28 | 2019-08-06 | 豪夫迈·罗氏有限公司 | 晚期her2表达性癌症的治疗 |
CR20190376A (es) | 2017-01-17 | 2019-11-20 | Genentech Inc | Formulaciones de anticuerpos de her2 subcutáneas |
EP3589661B1 (de) | 2017-03-02 | 2023-11-01 | Genentech, Inc. | Adjuvansbehandlung von her2-positivem brustkrebs |
TW201902509A (zh) | 2017-04-24 | 2019-01-16 | 美商建南德克公司 | Erbb2/her2突變 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935341A (en) * | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US5169774A (en) * | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US7838216B1 (en) * | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
US5401638A (en) * | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5824311A (en) * | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
DE69031120T2 (de) * | 1989-05-19 | 1998-01-15 | Genentech Inc | Her2 extrazellulare domäne |
US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US6884418B1 (en) * | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
WO1991002062A2 (en) * | 1989-08-04 | 1991-02-21 | Triton Biosciences, Inc. | C-erbb-2 external domain: gp75 |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
WO1991015230A1 (en) * | 1990-04-06 | 1991-10-17 | The Trustees Of The University Of Pennsylvania | Ligand for the neu gene product |
US5578482A (en) * | 1990-05-25 | 1996-11-26 | Georgetown University | Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses |
KR100246529B1 (ko) * | 1990-12-14 | 2000-04-01 | 스티븐 에이. 서윈. 엠.디. | 수용체 관련된 신호 변환 경로를 위한 키메라 사슬 |
US5571894A (en) * | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
US5367060A (en) * | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
US5834229A (en) * | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
CA2103059C (en) * | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
ATE176328T1 (de) * | 1991-08-22 | 1999-02-15 | Becton Dickinson Co | Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung |
US5288477A (en) * | 1991-09-27 | 1994-02-22 | Becton, Dickinson And Company | Method for prognosticating response to cancer therapy |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0625200B1 (de) * | 1992-02-06 | 2005-05-11 | Chiron Corporation | Marker für krebs und biosynthetisches bindeprotein dafür |
US5776427A (en) * | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
AU5355594A (en) * | 1992-10-09 | 1994-05-09 | Oncor, Inc. | Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
WO1995030331A1 (en) * | 1994-05-05 | 1995-11-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US5910486A (en) * | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5480698A (en) * | 1994-09-13 | 1996-01-02 | Hayman-Chaffey; Charles | Acrylic or polycarbonate sheet-lacquer laminates and articles of furniture made therefrom |
US5804396A (en) * | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5846749A (en) * | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
US5783404A (en) * | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
US5663144A (en) * | 1995-05-03 | 1997-09-02 | The Trustees Of The University Of Pennsylvania | Compounds that bind to p185 and methods of using the same |
US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
WO1997000271A1 (en) * | 1995-06-14 | 1997-01-03 | The Regents Of The University Of California | Novel high affinity human antibodies to tumor antigens |
CA2262403C (en) * | 1995-07-31 | 2011-09-20 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
IL127892A0 (en) * | 1996-07-12 | 1999-10-28 | Genentech Inc | Gamma-heregulin |
US5789522A (en) * | 1996-09-06 | 1998-08-04 | Shipley Company, L.L.C. | Resin purification process |
EP1695986B1 (de) * | 1996-10-18 | 2016-12-14 | Genentech, Inc. | Antikörper gegen Erb B2 |
US5885864A (en) * | 1996-10-24 | 1999-03-23 | Micron Technology, Inc. | Method for forming compact memory cell using vertical devices |
US5994071A (en) * | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6358682B1 (en) * | 1998-01-26 | 2002-03-19 | Ventana Medical Systems, Inc. | Method and kit for the prognostication of breast cancer |
US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
CA2357525A1 (en) * | 1999-01-27 | 2000-08-03 | Cornell Research Foundation, Inc. | Treating cancers associated with overexpression of her-2/neu |
US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
JP2004536561A (ja) * | 2000-12-01 | 2004-12-09 | レスポンス ジェネティクス,インコーポレイティド | 上皮増殖因子受容体及びHER2−neu遺伝子発現並びにそれらのレベルと生存との相関関係を決定する方法 |
US6582919B2 (en) * | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
-
2000
- 2000-06-23 AU AU54992/00A patent/AU779209B2/en not_active Ceased
- 2000-06-23 EP EP00939992A patent/EP1189634B1/de not_active Expired - Lifetime
- 2000-06-23 DK DK00939992T patent/DK1189634T3/da active
- 2000-06-23 DE DE60033658T patent/DE60033658T2/de not_active Expired - Lifetime
- 2000-06-23 KR KR1020017016538A patent/KR100754049B1/ko not_active IP Right Cessation
- 2000-06-23 MX MXPA01013395A patent/MXPA01013395A/es active IP Right Grant
- 2000-06-23 IL IL14701700A patent/IL147017A0/xx not_active IP Right Cessation
- 2000-06-23 CN CNB008108668A patent/CN100381172C/zh not_active Expired - Fee Related
- 2000-06-23 JP JP2001505945A patent/JP4579471B2/ja not_active Expired - Fee Related
- 2000-06-23 BR BR0012195-9A patent/BR0012195A/pt active Search and Examination
- 2000-06-23 CA CA2383493A patent/CA2383493C/en not_active Expired - Fee Related
- 2000-06-23 AT AT00939992T patent/ATE355079T1/de active
- 2000-06-23 ES ES00939992T patent/ES2282120T3/es not_active Expired - Lifetime
- 2000-06-23 WO PCT/US2000/017423 patent/WO2001000238A1/en active IP Right Grant
- 2000-06-23 PT PT00939992T patent/PT1189634E/pt unknown
-
2001
- 2001-12-07 ZA ZA200110088A patent/ZA200110088B/en unknown
-
2005
- 2005-09-23 US US11/234,586 patent/US20060083739A1/en not_active Abandoned
-
2007
- 2007-05-23 CY CY20071100697T patent/CY1107637T1/el unknown
-
2008
- 2008-10-08 US US12/247,850 patent/US20090087432A1/en not_active Abandoned
-
2009
- 2009-08-17 JP JP2009188783A patent/JP2009269928A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1189634A1 (de) | 2002-03-27 |
PT1189634E (pt) | 2007-06-06 |
CA2383493C (en) | 2010-08-10 |
JP2003503361A (ja) | 2003-01-28 |
CN1379684A (zh) | 2002-11-13 |
ES2282120T3 (es) | 2007-10-16 |
US20060083739A1 (en) | 2006-04-20 |
DE60033658T2 (de) | 2007-11-22 |
CY1107637T1 (el) | 2013-04-18 |
ATE355079T1 (de) | 2006-03-15 |
CN100381172C (zh) | 2008-04-16 |
WO2001000238A1 (en) | 2001-01-04 |
ZA200110088B (en) | 2002-08-26 |
MXPA01013395A (es) | 2003-09-04 |
CA2383493A1 (en) | 2001-01-04 |
JP2009269928A (ja) | 2009-11-19 |
KR20020069104A (ko) | 2002-08-29 |
BR0012195A (pt) | 2002-07-23 |
AU5499200A (en) | 2001-01-31 |
KR100754049B1 (ko) | 2007-08-31 |
DK1189634T3 (da) | 2007-06-25 |
EP1189634B1 (de) | 2007-02-28 |
AU779209B2 (en) | 2005-01-13 |
JP4579471B2 (ja) | 2010-11-10 |
US20090087432A1 (en) | 2009-04-02 |
DE60033658D1 (de) | 2007-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL147017A0 (en) | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES | |
PT1187632E (pt) | Tratamento com anticorpos anti-erbb2 | |
GB2368796A (en) | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies | |
CA2301032A1 (en) | A method of preventing or treating estrogen-dependent diseases and disorders | |
ATE239509T1 (de) | Konjugate zur behandlung von prostatakrebs | |
EP1320376A4 (de) | Behandlung von prostatakrebs | |
ZA200003236B (en) | Combination therapy for the treatment of migraine. | |
DZ2665A1 (fr) | Conjugués utiles pour le traitement du cancer de la prostate. | |
AP2004003070A0 (en) | The method of treating cancer. | |
WO2001053524A3 (en) | Cancer associated genes and their products | |
ZA200203166B (en) | Treatment of cancer. | |
ZA200002338B (en) | Combination therapy for the treatment of migraine. | |
WO2000004153A3 (en) | Repression of cell transformation with human pea3 | |
ZA200002343B (en) | Combination therapy for the treatment of migraine. | |
SI1585966T1 (sl) | Zdravljenje raka z anti-ErbB2 protitelesom rhuMAb 2C4 | |
ZA979655B (en) | Conjugates useful in the treatment of prostate cancer. | |
HK1034979A1 (en) | Conjugates useful in the treatment of prostate cancer. | |
AUPO851597A0 (en) | Treatment of prostate cancer | |
AU2002307428A1 (en) | Method of preventing or treating breast, prostate and/or cervical cancer with n,n-dimethylglycine | |
UA34368A (uk) | Спосіб лікування рака молочної залози | |
GB9804399D0 (en) | Conjugates useful in the treatment of prostate cancer | |
GB9810183D0 (en) | Conjugates useful in the treatment of prostate cancer | |
GB9815855D0 (en) | Conjugates useful in the treatment of prostate cancer | |
GB9617941D0 (en) | New approach to the treatment of prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HP | Change in proprietorship |
Owner name: GENENTECH, INC. Free format text: FORMER OWNERS:GENENTECH, INC.;SLOAN-KETTERING INSTITUTE FOR;CANCER RESEARCH |
|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |